Showing papers by "Clemens M. Wendtner published in 2017"
University of Bonn1, Hoffmann-La Roche2, University of California, San Diego3, Wellington Management Company4, Malaghan Institute of Medical Research5, University of Otago6, Halifax7, Ludwig Maximilian University of Munich8, Monash University, Clayton campus9, Tom Baker Cancer Centre10, AbbVie11, University of Ulm12, Erasmus University Rotterdam13, Genentech14
TL;DR: Venetoclax is a potent BH3-mimetic compound that selectively antagonizes BCL-2 and has shown efficacy as monotherapy and withdrawal from chronic lymphocytic leukemia.
99 citations